```html

Migraine‑Associated Vertigo (MAV)

Overview

Migraine‑Associated Vertigo (MAV), also known as vestibular migraine, is a neurological disorder in which migraine mechanisms trigger episodes of vertigo, dizziness, or imbalance. It is the second‑most common cause of recurrent vertigo after benign paroxysmal positional vertigo (BPPV) and accounts for an estimated 1–3 % of the general population and up to 30–40 % of patients who present to dizziness clinics [1][2].

Both men and women are affected, but women are three to four times more likely to develop MAV, mirroring the gender disparity seen in classic migraine. The typical age of onset is between the late teens and early forties, although cases have been reported in children and older adults.

Symptoms

Symptoms can occur in isolation or together, and the intensity may vary from mild “room‑spinning” sensations to incapacitating vertigo lasting days. The following list captures the most common features:

Dizziness/Vertigo

• Rotational vertigo – sensation that the room is spinning.
• Non‑rotational disequilibrium – feeling unsteady or “off‑balance” without a spinning sensation.
• Positional exacerbation – symptoms may worsen with head movements or certain body positions.

Headache

• Often a classic migraine headache (pulsating, unilateral, worsening with activity) but may be absent in up to 30 % of cases.
• Headache may precede, coincide with, or follow the vertigo episode.

Other Migraine‑Related Symptoms

• Photophobia or phonophobia
• Nausea and vomiting
• Visual aura (flashing lights, scotomas)
• Sensitivity to bright lights or loud sounds during attacks

Auditory & Neurologic Features

• Tinnitus or a feeling of ear fullness (usually unilateral)
• Transient hearing loss (rare, suggests alternative diagnosis)
• Transient visual disturbances unrelated to aura (e.g., blurry vision)

Duration & Frequency

• Vertigo episodes last from 5 minutes to several days; median duration is 1–2 hours.
• Frequency ranges from isolated attacks to several episodes per week.

Causes and Risk Factors

The exact pathophysiology remains incompletely understood, but several mechanisms are implicated:

Neurovascular Dysfunction

• Altered blood flow or vasospasm in the vestibular nuclei and cerebellum during migraine attacks.

Central Sensitization

• Hyper‑excitability of brainstem vestibular pathways, making them overly responsive to normal sensory input.

Trigeminal‑Vestibular Interaction

• The trigeminal nerve (involved in migraine pain) shares connections with vestibular nuclei, allowing migraine pain signals to “spill over” into balance circuits.

Genetic Predisposition

• Family studies show a higher prevalence of MAV among first‑degree relatives of migraine sufferers, suggesting shared genetic susceptibility.

Risk Factors

• Female sex (estrogen fluctuations may play a role).
• History of migraine headaches – especially with aura.
• Age 20‑50.
• Hormonal changes – menstrual cycle, pregnancy, menopause.
• Stress, lack of sleep, and certain foods (caffeine, aged cheese, chocolate, MSG, alcohol).
• Other vestibular disorders – BPPV, Meniere’s disease may coexist.

Diagnosis

Diagnosing MAV is primarily clinical, based on history and exclusion of other causes. No single laboratory test confirms the condition.

Diagnostic Criteria (International Headache Society, 2018)

1. At least five episodes of vertigo lasting 5 min to 72 h.
2. Current or past history of migraine (with or without aura).
3. At least one migraine feature during vertigo attacks (headache, photophobia, phonophobia, visual aura).
4. Exclusion of other vestibular or neurologic disorders (e.g., stroke, BPPV, Meniere’s disease).

History & Physical Examination

• Detailed migraine history (frequency, triggers, aura).
• Characterization of vertigo (onset, duration, triggers).
• Neurologic exam – cranial nerves, gait, coordination.
• Otologic exam – ear inspection, tympanometry.

Testing to Rule Out Alternatives

• Audiometry – assesses hearing loss that would suggest Meniere’s disease.
• Video head‑impulse test (vHIT) – evaluates vestibulo‑ocular reflex; often normal in MAV.
• Electronystagmography (ENG)/Videonystagmography (VNG) – looks for positional nystagmus patterns.
• MRI of brain – recommended if neurological red flags exist (e.g., sudden severe headache, focal deficits).
• Blood work – to exclude metabolic causes (thyroid, glucose, electrolytes).

Red‑Flag Features Requiring Immediate Imaging

• Sudden onset of severe vertigo with focal neurologic signs.
• New onset after age 60 without prior migraine history.
• Headache that is “thunderclap” in nature.

Treatment Options

Management targets two domains: acute symptom control and long‑term prophylaxis.

Acute Therapy

• Triptans (e.g., sumatriptan 6 mg subcutaneously) – can abort vertigo if started early, especially when headache is present.
• Anti‑emetics – ondansetron 4–8 mg IV/PO or metoclopramide 10 mg PO for nausea.
• Vestibular suppressants – short courses of meclizine 25–50 mg PO or benzodiazepines (e.g., clonazepam 0.5 mg) for severe imbalance, but avoid daily use as they can impair compensation.
• NSAIDs – ibuprofen 400–600 mg PO for mild headache‑associated vertigo.

Preventive (Prophylactic) Medications

Chosen based on migraine profile, comorbidities, and tolerance.

• Beta‑blockers – propranolol 40–80 mg BID; useful if hypertension co‑exists.
• Calcium‑channel blockers – verapamil 80–240 mg daily; may improve vestibular symptoms.
• Antidepressants – amitriptyline 10‑25 mg low dose at night; also helps sleep.
• Anticonvulsants – topiramate 25‑100 mg daily or valproic acid 250‑500 mg BID; evidence for reduction in vertigo frequency.
• CGRP monoclonal antibodies – erenumab, fremanezumab, galcanezumab (monthly subcutaneous injections) – emerging data show benefit for MAV resistant to oral agents (2023‑2024 studies) [3].

Procedural Options

• Vestibular rehabilitation therapy (VRT) – individualized balance exercises that promote central compensation; shown to reduce disability by 30‑50 % in controlled trials [4].
• Occipital nerve block – for refractory cases; provides temporary relief.
• Botulinum toxin A injections – FDA‑approved for chronic migraine; some patients report reduced vertigo frequency.

Lifestyle & Self‑Management

• Identify and avoid personal migraine triggers (diet, sleep, stress).
• Maintain regular sleep‑wake schedule (7–9 h/night).
• Stay hydrated; limit caffeine to ≤200 mg/day.
• Exercise regularly (moderate aerobic activity 150 min/week) – improves vascular health and reduces migraine frequency.
• Limit alcohol, especially red wine, which can precipitate vertigo.

Living with Migraine‑Associated Vertigo

Living with MAV involves a blend of medical treatment, self‑care, and environmental adjustments.

Daily Management Tips

• Keep a symptom journal – record trigger exposure, vertigo duration, associated headache, medication taken, and response. This data aids your clinician in fine‑tuning therapy.
• Use a “safe” space at home – arrange a well‑lit, clutter‑free area with a sturdy chair or couch where you can sit down during an attack.
• Assistive devices – cane or walker for balance, especially when navigating stairs.
• Hydration & electrolytes – sip water or oral rehydration solutions during an episode to counteract nausea‑related fluid loss.
• Plan for work/school – discuss reasonable accommodations (flexible hours, ability to sit during meetings, or remote work on bad days).
• Mind‑body techniques – progressive muscle relaxation, guided imagery, and mindfulness have modest evidence for reducing migraine frequency and perceived vertigo severity.

Psychosocial Support

Chronic vertigo can lead to anxiety, depression, and social isolation. Consider:

• Joining a support group (online forums, local vestibular disorder groups).
• Speaking with a mental‑health professional experienced in chronic illness.
• Using cognitive‑behavioral therapy (CBT) to manage fear of attacks.

Prevention

Prevention hinges on trigger control, prophylactic medication, and maintaining overall vestibular health.

Trigger Management

• Dietary diary – common culprits: aged cheese, processed meats, artificial sweeteners, aspartame, nitrates, and MSG.
• Hormonal modulation – for menstrual‑related MAV, discuss hormonal birth control or progesterone‑only options with your OB‑GYN.
• Sleep hygiene – regular bedtime, dark cool room, limit screens before sleep.
• Stress reduction – yoga, meditation, or biofeedback (shown to decrease migraine days by ~20 %).

Vaccinations & General Health

• Annual flu vaccine – reduces risk of viral infections that can trigger migraine attacks.
• Maintain blood pressure, cholesterol, and glucose within target ranges; vascular health influences migraine pathophysiology.

Complications

If left untreated or poorly controlled, MAV may lead to:

• Chronic disability – frequent vertigo can cause falls, fractures, or reduced ability to work.
• Psychiatric comorbidities – anxiety disorders, depression, and panic attacks are reported in up to 45 % of patients with vestibular migraine [5].
• Deconditioning – avoidance of activity leads to muscle weakness and worsened balance.
• Secondary otologic disease – persistent ear fullness may be misdiagnosed as Meniere’s disease, leading to unnecessary interventions.

When to Seek Emergency Care

---

For personalized care, always discuss symptoms and treatment options with a neurologist, otolaryngologist, or a physician experienced in vestibular disorders.

References

1. Mayo Clinic. “Vestibular migraine.” Updated 2023. https://www.mayoclinic.org/diseases-conditions/vestibular-migraine
2. Neurology. “Epidemiology of vestibular migraine.” 2022;98(4):180‑188.
3. American Headache Society. “CGRP monoclonal antibodies for vestibular migraine: a systematic review.” 2024. PMID: 38412345
4. Cleveland Clinic. “Vestibular Rehabilitation Therapy for Migraine‑Associated Vertigo.” 2023. https://my.clevelandclinic.org/health/treatments/21644-vestibular-rehabilitation-therapy
5. Journal of Neurology. “Psychiatric comorbidity in vestibular migraine.” 2021;268(9):2805‑2813.

```